Sysmex CZ & SK
Menu

Sentimag - Magseed

Due to improvements in screening and patient awareness, approximately 50% of breast lesions are impalpable at the time of diagnosis. The current gold standard to assist the surgeon in finding an impalpable lesion is a hookwire, or guidewire. These are usually placed on the morning of surgery. Wire-guided localisations (WGL) have been used since the 1960s and have several limitations, including migration of the wire, scheduling conflicts and patient dissatisfaction.

Magseed® has been specifically developed to overcome these issues. It promotes seamless operating room (OR) scheduling, accurate lesion localisation and patient satisfaction.

Our system consists of the Sentimag® probe and the Magseed® magnetic marker. First, the marker is placed under ultrasound or X-ray guidance up to 30 days before surgery. In the OR, the surgeon uses Sentimag® to precisely localise Magseed® and therefore the lesion.

 

Magseed® – Benefits for all

  • Organise the lesion localisation procedure to suit your needs
  • Can be placed 30 days in advance – better for patients, better for the clinical workflow
  • Greatly improved OR and radiology scheduling
  • 360-degree sensing and distance calculation for the best oncoplastic approach
  • Patient-centric approach: no radioactivity, reduced stress, minimal invasiveness
  • Sentimag® and Magseed® are FDA-cleared and CE-marked for lesion localisation

 

Endomag®, Sentimag®, Magseed® and Sienna+® are registered European Community Trademarks of Endomagnetics Ltd. www.endomag.com.

Kontaktujte nás
You have a question and would like to get in touch with our experts? We look forward to receiving your enquiry.

Sysmex CZ s.r.o.

Plynárenská 499/1

602 00 Brno

+420 548 216 855

+420 548 216 343

Sysmex Slovakia s.r.o.

Trenčianská 47

821 09 Bratislava

+421 2 6453 2881-2

+421 2 6428 1651

Explore more

ONCOBEAM CRC RAS KIT

ONCOBEAM CRC RAS KIT

Clinically actionable information with a simple blood draw

Detail
OSNA in breast cancer

OSNA in breast cancer

More differentiated information to fine-tune your treatment decision

Detail
RD-210

RD-210

OSNA – Advanced platform for analysing lymph nodes

Detail
Copyright © Sysmex Europe SE. All rights reserved.